Limited domestic vaccine manufacturing endangers U.S. flu prep, GAO report says

The observations come courtesy of a new U.S. Government Accountability Office (GAO) report examining the country’s avian flu efforts, compiled as requested by Congress.  About 90% to 95% of the current national stockpile of pandemic flu vaccines is produced with chicken eggs, the report says, based on the account of a Department of Health and Human Services (DHHS) official.  Four (4) companies contribute to the stockpile, but only one has an egg-based vaccine manufacturing facility in the country.

The report did not identify that lone company; however, Sanofi Pasteur has a site in Pennsylvania and has previously entered into HHS contracts to ensure egg supply for vaccine production.  The report did point out that there are poultry raised specifically for producing eggs to make human vaccines.  A Sanofi spokesperson declined to confirm whether the French drug giant is the company mentioned in the report.

Having domestic vaccine supplies is particularly important because, once a worldwide influenza pandemic hits, vaccines may be tough to come by, according to the report.  In that case, “the U.S. government may not be able to rely on foreign countries to allow exports of pandemic vaccine,” the authors state.  Therefore, the U.S. government only has one “dependable manufacturer for producing egg-based vaccine for rapid pandemic mitigation,” said the report.

DHHS is well aware of that risk and has contracted with Sanofi to ensure a year-round supply of eggs.  In October 2010, HHS awarded a $57 million federal contract to Sanofi, renewing an older 2004 contract.  In September 2014, the Agency handed out another $42 million for the cause.  However, there is a solution to this problem:  changing to cell-based or recombinant technologies to produce vaccines.

In 2012, FDA approved then Novartis’ Flucelvax, the first U.S.-licensed seasonal flu vaccine manufactured using cell culture technology.  CSL has since picked up Novartis’ flu offerings.

Just a few weeks ago, by request of DHHS, Protein Sciences embarked on the development of two H7N9 vaccine candidates using recombinant technology.  The vaccine maker touted the fast production of its recombinant vaccine compared to traditional egg-based flu vaccines.

Elsewhere, three (3) Centers for Innovation in Advanced Development and Manufacturing are seeking to provide “a significant domestic infrastructure” in the U.S. for protection against bioterrorism and pandemic influenza, and potentially to assist with the phase-out of egg-based vaccines.  The three (3) locations include one (1) in Texas by the Texas A&M University System, one (1) Emergent Biosolutions’ facility in Maryland, and one (1) in North Carolina that Australia’s CSL bought in 2015 from Novartis together with the latter’s flu vaccine business.

However, according to DHHS’s Office of the Assistant Secretary for Preparedness and Response, it is still unclear when the three (3) Centers would be fully operational to be able to manufacture the contracted quantity of pandemic influenza vaccine.

REFERENCE:  Fierce Pharma; 16 MAY 2017; Angus Liu

Leave a Comment